Food and Drug Administration closely monitors diet pills containing **** ingredients

The U.S. Food and Drug Administration recently stated that due to clinical trials showing that the weight loss drug Noume Ting can increase the risk of heart attack and stroke in users, the weight loss drug maker Abbott USA has agreed to withdraw it from the US market. The reporter learned from Abbott China today that the company’s last batch of Connaught was imported in June 2008. Since then, the drug has not been imported; this batch of imported drugs expired in January of this year. At present, there is no drug in the Beijing market. Sale. The reporter did not see Nuomei Ting in pharmacies such as Golden Elephant Pharmacy.

Nuo Mei Ting was approved by the US Food and Drug Administration in 1997 for weight loss. The clinical data at that time showed that the users of Noumetin could lose about 5% of their body weight on average. The follow-up investigation conducted by the European drug regulatory authority after approving the listing of Namimeiting found that the risk of serious cardiac events such as heart attack and stroke was higher in Nomura Ting users than in those taking placebo, and the weight of the two groups of people The difference is small. According to the US Drug Administration, taking into account that Connaught has caused heart disease, stroke risk, and very limited weight loss, the drug should no longer continue to be sold, and obese patients should consult a doctor to switch to other diet pills.

It is understood that there are some slimming medicines in our country that contain the same ingredient as sibutramine, which increases the risk of heart attack and stroke. The State Food and Drug Administration stated that it is closely monitoring the safety and adverse reactions of all products containing “Sibutramine” diet pills sold on the domestic market, and requires related companies to modify drug descriptions to prompt patients and doctors of known and Potential drug risks. In the next step, based on the monitoring results, reference will be made to the regulatory measures of drug regulatory authorities in other countries, and corresponding regulatory measures will be taken in light of China's situation.